Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Last trade$32.83
Day change-$0.135 (-0.41%)
Day range$32.44 – $33.32
Volume260,142
Market cap$1.94B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.94B
Price / earnings
10.84×
Price / book
1.81×
Price / sales
1.96×
EV / sales
1.45×
EV / EBITDA
5.87×
Profitability
Earnings per share
$3.04
Return on assets
12.08%
Return on equity
16.66%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.14×
Current ratio
3.44×
Quick ratio
3.42×
Cash ratio
2.38×
Cash flow
Price / cash flow
5.99×
Price / free cash flow
5.99×
Free cash flow
$322.93M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for HRMY, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$268.92M
$261.28M
$215.39M
$243.78M
$239.46M
$200.49M
$184.73M
$201.27M
Cost of revenue
$80.69M
$63.2M
$44.51M
$68.55M
$59.65M
$38.15M
$31.99M
$54.41M
Gross profit
$188.23M
$198.08M
$170.88M
$175.23M
$179.81M
$162.34M
$152.74M
$146.86M
Selling, general and administrative
$62.37M
$62.17M
$64.2M
$86.74M
$59.36M
$64M
$61.95M
$56.47M
Research and development
$71.66M
$46.6M
$69.38M
$49.93M
$54.96M
$50.16M
$34.54M
$34.67M
Total operating expenses
$134.03M
$108.77M
$133.58M
$136.67M
$114.32M
$114.16M
$96.49M
$91.13M
Operating income
$54.2M
$89.32M
$37.29M
$38.56M
$65.49M
$48.18M
$56.25M
$55.73M
Interest expense
-$3.06M
-$2.92M
-$3.23M
-$3.55M
-$3.62M
-$3.48M
-$3.84M
-$4.21M
Income before taxes
$59.25M
$93.27M
$39.69M
$40.76M
$67.49M
$49.64M
$57.18M
$56.16M
Income taxes
$11.05M
$17.83M
$7.2M
$18.27M
$16.63M
$9.86M
$11.62M
$6.68M
Net income
$48.2M
$75.43M
$32.49M
$22.49M
$50.87M
$39.78M
$45.56M
$49.48M
Net income attributable to common shareholders
$48.2M
$75.43M
$32.49M
$22.49M
$50.87M
$39.78M
$45.56M
$49.48M
EBITDA
$72.09M
$83.36M
$43.26M
$45.99M
$83.38M
$42.23M
$62.21M
$61.7M
Basic earnings per share
$0.83
$1.30
$0.56
$0.39
$0.88
$0.69
$0.79
$0.87
Diluted earnings per share
$0.81
$1.28
$0.55
$0.38
$0.87
$0.68
$0.78
$0.85
Recent news
Company coverage with links to the original publishers.
The American Academy of Sleep Medicine released a comprehensive report and multiyear roadmap to improve women's sleep health, identifying priority areas including fertility, pregnancy, postpartum health, menopausal transitions, and sleep disorders. The report highlights gaps in research, clinical care, and policy, calling for increased clinical trial representation, research funding, and tailored interventions for women.
Harmony Biosciences reported Q3 EPS of 81 cents, missing consensus estimates of $1.00, despite 12% revenue growth to $269 million. Higher R&D spending, a $25 million MSN milestone charge, and royalty expenses pressured profitability. The company reaffirmed its 2026 Wakix revenue guidance of $1-$1.04 billion, supported by sustained patient demand and 400 net patient additions. The pipeline includes promising Phase I results for BP-205 and ongoing late-stage studies for pitolisant formulations and epilepsy programs.
Harmony Biosciences is expected to report Q3 2026 earnings on November 4, with Wall Street anticipating 14.9% YoY EPS growth to $1.00 per share and 13.1% revenue growth to $270.87 million. However, a negative Earnings ESP of -12.00% combined with recent downward estimate revisions suggests the stock may not beat consensus expectations, despite carrying a Zacks Rank #1 rating.
Bausch Health Companies (BHC) is scheduled to report Q3 2026 results on October 28 with consensus estimates of $2.75 billion in sales and $1.08 EPS. The company has a Zacks Rank of 2 (Buy) with 0% Earnings ESP, suggesting limited upside surprise potential. Growth is expected across Salix (driven by Xifaxan pricing and volume), Bausch + Lomb Vision Care and Surgical divisions, and international operations, though the stock has already gained 15.4% over the past six months.
Tango Therapeutics shares dropped 16.4% after updated phase I/II data showed an 82% objective response rate in pancreatic cancer, down from 92% in June's initial readout. While the combination demonstrated durable disease control with 88% nine-month progression-free survival, the company also announced a 14% workforce reduction and R&D reprioritization focusing on PRMT5 programs. Tango plans to initiate a phase III study in 2027.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.